Frank Vinluan / medcitynews - Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favo…
#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #pfizer #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment
Monday, November 10, 2025, 12:21 am / permalink 15823 / 4 stories in 4 months
Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)
GLP‑1 drugs associated with lower addiction risk in large study (4 days)
Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines (8 days)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.